Sample Page hero background

Investors

page background

Investor Relations

Corporate Profile

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the development of novel therapeutic agents, including small molecule Selective Inhibitor of Nuclear Export, or SINE™, compounds that inhibit the nuclear export protein XPO1. Selinexor, a SINE™ compound and Karyopharm’s lead drug candidate, is currently in registration-directed clinical trials in various hematological malignancies and Phase 2 clinical trials in multiple solid tumor indications. Related compounds have also been investigated in preclinical models and are advancing towards clinical trials in wound healing, viral infections and autoimmune and inflammatory diseases. Karyopharm was founded by Dr. Sharon Shacham in December 2008 and is headquartered in Newton, Massachusetts.

Shareholder Tools